One of the biggest challenges to new financing models for innovative therapies the 1990 Medicaid “best price” rules, which ensures that the Medicaid program receives discounts at least as large as commercial payers. But CMS is implementing a new rule in January 2023 for tiered MBP reporting based on performance. Important questions about implementation, participation, and pricing persist. Panelists in this webinar will bring both quantitative analysis and practical experience perspectives to bear on the issues.